Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. (Q46547397)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 June 2008

Language	Label	Description	Also known as
English	Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.	scientific article published on 9 June 2008

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

0 references

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Shih-Ci Ciou

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Chau-Ming Cheng

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Lyu-Han Wang

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Jhao-Hao Hong

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Ming-Yan Jheng

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Szu-Ting Ling

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Yun-Wei Lin

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

0 references

publication date

9 June 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

29

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1448-1458

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

The epidermal growth factor receptor as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Cellular pharmacology of quinone bioreductive alkylating agents

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC--a phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

The RAD51 protein supports homologous recombination by an exchange mechanism in mammalian cells

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Coordinating ERK/MAPK signalling through scaffolds and inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Persistent activation of ERK1/2 by lead acetate increases nucleotide excision repair synthesis and confers anti-cytotoxicity and anti-mutagenicity

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Basis for effective combination cancer chemotherapy with antimetabolites

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Cellular localization of human Rad51C and regulation of ubiquitin-mediated proteolysis of Rad51

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Multidisciplinary management of lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

The resurgence of platinum-based cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Mechanisms of resistance to cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Targeted disruption of the Rad51 gene leads to lethality in embryonic mice

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Homologous recombinational repair vis-à-vis chlorambucil resistance in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Double bolt regulation of Rad51 by p53: a role for transcriptional repression.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGN130

21 January 2018

Identifiers

10.1093/CARCIN/BGN130

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18544565%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46547397&oldid=1247085941"